{"id":"https://openalex.org/W2404743526","doi":null,"title":"Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.","display_name":"Role of 131I-metaiodobenzylguanidine (MIBG) in the treatment of neuroendocrine tumours. Experience of the National Cancer Institute of Milan.","alternate_titles":[],"publication_year":2000,"publication_date":"2000-03-01","ids":{"openalex":"https://openalex.org/W2404743526","mag":"2404743526","pmid":"https://pubmed.ncbi.nlm.nih.gov/10932604"},"language":"en","primary_location":{"id":"pmid:10932604","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10932604","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)","raw_type":"Journal Article"},"parent_works":[],"lineage":["https://openalex.org/W2404743526"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5091282872","display_name":"Maria Rita Castellani","orcid":"https://orcid.org/0000-0001-7335-7842","observed_orcids":["https://orcid.org/0000-0001-7335-7842"]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"M R Castellani","raw_affiliation_strings":["Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Nuclear Medicine Division, Istituto Nazionale per lo Studio e la Cura dei Tumori, Milano, Italy","institution_ids":["https://openalex.org/I4210156707"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5089626999","display_name":"Arturo Chiti","orcid":"https://orcid.org/0000-0002-5806-1856","observed_orcids":["https://orcid.org/0000-0002-5806-1856"]},"institutions":[{"id":"https://openalex.org/I4210163047","display_name":"IRCCS Humanitas Research Hospital","ror":"https://ror.org/05d538656","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210163047"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"A Chiti","raw_affiliation_strings":["Istituto Clinico Humanitas"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Istituto Clinico Humanitas","institution_ids":["https://openalex.org/I4210163047"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088022548","display_name":"Ettore Cesare Seregni","orcid":"https://orcid.org/0000-0002-5097-049X","observed_orcids":["https://orcid.org/0000-0002-5097-049X"]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"E Seregni","raw_affiliation_strings":["Fondazione IRCCS Istituto Nazionale dei Tumori"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fondazione IRCCS Istituto Nazionale dei Tumori","institution_ids":["https://openalex.org/I4210156707"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5054372316","display_name":"Emilio Bombardieri","orcid":"https://orcid.org/0000-0003-4063-8167","observed_orcids":["https://orcid.org/0000-0003-4063-8167"]},"institutions":[{"id":"https://openalex.org/I4210156707","display_name":"Fondazione IRCCS Istituto Nazionale dei Tumori","ror":"https://ror.org/05dwj7825","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I4210156707"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"E Bombardieri","raw_affiliation_strings":["Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan (Italy). Nuclear Medicine Division"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Istituto Nazionale per lo Studio e la Cura dei Tumori, Milan (Italy). Nuclear Medicine Division","institution_ids":["https://openalex.org/I4210156707"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":1.3842,"has_fulltext":false,"cited_by_count":61,"citation_normalized_percentile":{"value":0.80232132,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"44","issue":"1","first_page":"77","last_page":"87"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.6244999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10754","display_name":"Neuroendocrine Tumor Research Advances","score":0.6244999766349792,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12226","display_name":"Neuroblastoma Research and Treatments","score":0.3068999946117401,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11395","display_name":"Radiopharmaceutical Chemistry and Applications","score":0.03869999945163727,"subfield":{"id":"https://openalex.org/subfields/2741","display_name":"Radiology, Nuclear Medicine and Imaging"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/131i-mibg-therapy","display_name":"131I-MIBG therapy","score":0.906000018119812},{"id":"https://openalex.org/keywords/metaiodobenzylguanidine","display_name":"metaiodobenzylguanidine","score":0.8690000176429749},{"id":"https://openalex.org/keywords/neuroendocrine-tumors","display_name":"neuroendocrine tumors","score":0.9309999942779541},{"id":"https://openalex.org/keywords/neuroblastoma","display_name":"neuroblastoma","score":0.9729999899864197},{"id":"https://openalex.org/keywords/pheochromocytoma","display_name":"pheochromocytoma","score":0.9940000176429749},{"id":"https://openalex.org/keywords/paraganglioma","display_name":"paraganglioma","score":0.9860000014305115},{"id":"https://openalex.org/keywords/medullary-thyroid-carcinoma","display_name":"medullary thyroid carcinoma","score":0.9990000128746033},{"id":"https://openalex.org/keywords/carcinoid-tumor","display_name":"carcinoid tumor","score":0.8610000014305115},{"id":"https://openalex.org/keywords/radioactive-iodine-therapy","display_name":"radioiodine therapy","score":0.7089999914169312},{"id":"https://openalex.org/keywords/mibg-scintigraphy","display_name":"MIBG scintigraphy","score":0.7580000162124634},{"id":"https://openalex.org/keywords/treatment-response","display_name":"treatment response","score":0.746999979019165},{"id":"https://openalex.org/keywords/toxicity","display_name":"toxicity","score":0.4909999966621399},{"id":"https://openalex.org/keywords/metastatic-disease","display_name":"metastatic disease","score":0.6060000061988831},{"id":"https://openalex.org/keywords/residual-tumor","display_name":"residual tumor","score":0.6740000247955322}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.9105243682861328},{"id":"https://openalex.org/C2776715637","wikidata":"https://www.wikidata.org/wiki/Q938205","display_name":"Neuroblastoma","level":3,"score":0.8049734830856323},{"id":"https://openalex.org/C2993559085","wikidata":"https://www.wikidata.org/wiki/Q2126444","display_name":"Radionuclide therapy","level":2,"score":0.7136273384094238},{"id":"https://openalex.org/C2780120053","wikidata":"https://www.wikidata.org/wiki/Q3493538","display_name":"Medullary thyroid cancer","level":4,"score":0.6702666878700256},{"id":"https://openalex.org/C2776734335","wikidata":"https://www.wikidata.org/wiki/Q581592","display_name":"Paraganglioma","level":2,"score":0.6499208807945251},{"id":"https://openalex.org/C2779066768","wikidata":"https://www.wikidata.org/wiki/Q1981276","display_name":"Neuroendocrine tumors","level":2,"score":0.623711109161377},{"id":"https://openalex.org/C2778822529","wikidata":"https://www.wikidata.org/wiki/Q1951525","display_name":"Progressive disease","level":3,"score":0.5932602286338806},{"id":"https://openalex.org/C2779902710","wikidata":"https://www.wikidata.org/wiki/Q1130465","display_name":"Scintigraphy","level":2,"score":0.5530967712402344},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4987828731536865},{"id":"https://openalex.org/C2776694085","wikidata":"https://www.wikidata.org/wiki/Q974135","display_name":"Chemotherapy","level":2,"score":0.4852590262889862},{"id":"https://openalex.org/C121608353","wikidata":"https://www.wikidata.org/wiki/Q12078","display_name":"Cancer","level":2,"score":0.3813183307647705},{"id":"https://openalex.org/C143998085","wikidata":"https://www.wikidata.org/wiki/Q162555","display_name":"Oncology","level":1,"score":0.37293732166290283},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.3589686155319214},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.3489198088645935},{"id":"https://openalex.org/C2779761222","wikidata":"https://www.wikidata.org/wiki/Q826522","display_name":"Thyroid cancer","level":3,"score":0.30631524324417114},{"id":"https://openalex.org/C126838900","wikidata":"https://www.wikidata.org/wiki/Q77604","display_name":"Radiology","level":1,"score":0.26791536808013916},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.0},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.0},{"id":"https://openalex.org/C81885089","wikidata":"https://www.wikidata.org/wiki/Q189082","display_name":"Cell culture","level":2,"score":0.0}],"mesh":[{"descriptor_ui":"D000293","descriptor_name":"Adolescent","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002648","descriptor_name":"Child","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D002675","descriptor_name":"Child, Preschool","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011877","descriptor_name":"Radionuclide Imaging","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000000981","qualifier_name":"diagnostic imaging","is_major_topic":false},{"descriptor_ui":"D018358","descriptor_name":"Neuroendocrine Tumors","qualifier_ui":"Q000532","qualifier_name":"radiotherapy","is_major_topic":true},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019275","descriptor_name":"Radiopharmaceuticals","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019797","descriptor_name":"3-Iodobenzylguanidine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D019797","descriptor_name":"3-Iodobenzylguanidine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"pmid:10932604","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10932604","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR)","raw_type":"Journal Article"},{"id":"mag:2404743526","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/10932604","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":"PubMed","raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2407744563","https://openalex.org/W1841247142","https://openalex.org/W2055454912","https://openalex.org/W2794759581","https://openalex.org/W2168989838","https://openalex.org/W2165205961","https://openalex.org/W1973526308","https://openalex.org/W2018642945","https://openalex.org/W2143973920","https://openalex.org/W3021882287"],"abstract_inverted_index":{"BACKGROUND:":[0],"45":[1],"patients":[2,91,101,115,133,159,191,239,251,300],"with":[3,25,32,39,48,54,102,116,134,160,252,264,278],"neuroendocrine":[4],"tumours":[5],"(22":[6],"neuroblastomas,":[7],"10":[8],"phaeochromocytomas,":[9],"3":[10,153,170,179,199,285],"para-gangliomas,":[11],"6":[12],"medullary":[13,253],"thyroid":[14,254],"carcinomas":[15],"and":[16,152,205,223,246,267,328],"4":[17],"carcinoids)":[18],"underwent":[19,281],"131I-MIBG":[20,49,324],"therapy.":[21,129],"METHODS:":[22],"All":[23,79],"patients,":[24],"the":[26,97,111,187,210,215,221,231,235,296,315],"exception":[27],"of":[28,70,143,155,166,183,189,195,198,209,217,237,298,317],"5":[29,202],"phaeochromocytoma":[30,190],"cases":[31],"nonoperable":[33],"disease,":[34],"had":[35,43,301,302],"previously":[36],"been":[37],"treated":[38],"conventional":[40],"therapies.":[41],"Patients":[42,277],"a":[44,146,173,256],"previous":[45,109,139,303],"diagnostic":[46],"scintigraphy":[47],"(activity":[50,56],"20-44.4":[51],"MBq)":[52],"or":[53,310],"123I-MIBG":[55],"74-222":[57],"MBq).":[58],"The":[59,89,181,288],"therapeutic":[60],"activity":[61],"for":[62,72],"adults":[63],"ranged":[64],"from":[65,74],"3.7":[66],"to":[67,76,108,138],"7.4":[68],"GBq":[69],"131I-MIBG;":[71],"children":[73],"2.7":[75],"5.5":[77],"GBq.":[78],"treatments":[80,305],"were":[81,92,271],"repeated":[82],"at":[83],"not":[84,106,123],"less":[85],"than":[86],"4-weekly":[87],"intervals.":[88],"neuroblastoma":[90,119,132,158],"divided":[93],"into":[94],"two":[95],"groups:":[96],"first":[98],"included":[99,113],"14":[100,144],"advanced":[103,135],"metastatic":[104],"disease":[105,136,151,162,204,269,286],"responding":[107],"treatments;":[110],"second":[112],"8":[114],"documented":[117],"residual":[118,161],"tissue":[120],"that":[121,295,323],"could":[122],"be":[124],"surgically":[125],"removed":[126],"after":[127],"first-line":[128],"RESULTS:":[130],"In":[131,157,234,250],"resistant":[137],"therapies":[140],"2":[141,268,275],"out":[142,165,194,213],"showed":[145,226,284],"partial":[147,171,200,245,257],"response,":[148],"9":[149],"stable":[150,174,203,248],"progression":[154],"cancer.":[156],"(7":[163],"evaluable":[164,193],"8)":[167],"we":[168,240,320],"obtained":[169],"responses;":[172],"response":[175,211,258],"was":[176,259,291],"observed":[177,241,260],"in":[178,186,229,261,273,311],"patients.":[180,276],"results":[182],"MIBG":[184,224,282],"therapy":[185,225,283,325],"group":[188,236],"(9":[192],"10)":[196],"consisted":[197],"responses,":[201],"1":[206,242,244,247,262],"progression.":[207],"Evaluation":[208],"carried":[212],"on":[214],"basis":[216,316],"biochemical":[218],"parameters":[219],"increased":[220],"responses":[222],"good":[227],"effectiveness":[228],"controlling":[230],"functional":[232],"symptoms.":[233],"paraganglioma":[238],"complete,":[243],"response.":[249],"carcinoma":[255],"patient":[263],"mediastinal":[265],"metastases":[266],"stabilisations":[270],"seen":[272],"another":[274],"carcinoids":[279],"who":[280],"stabilisations.":[287],"overall":[289],"toxicity":[290],"acceptable,":[292],"especially":[293],"considering":[294],"majority":[297],"our":[299,318],"myelotoxic":[304],"(chemotherapy":[306],"and/or":[307],"radiotherapy,":[308],"alone":[309],"combination).":[312],"CONCLUSIONS:":[313],"On":[314],"experience":[319],"can":[321],"conclude":[322],"is":[326],"effective":[327],"also":[329],"well":[330],"tolerated.":[331]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2404743526","counts_by_year":[{"year":2023,"cited_by_count":1},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":5},{"year":2019,"cited_by_count":1},{"year":2017,"cited_by_count":2},{"year":2016,"cited_by_count":5},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":1},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2016-06-24T00:00:00"}
